⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19943585 | 1.00 | — | — | |
| SCHEMBL26495534 | 1.00 | — | — | |
| SCHEMBL4630592 | 0.82 | KDM4E (0.32) | — | |
| SCHEMBL27272783 | 0.80 | SLC6A1 (0.33) | — | |
| SCHEMBL25897056 | 0.79 | — | — | |
| SCHEMBL6292661 | 0.79 | — | — | |
| SCHEMBL25897069 | 0.79 | — | — | |
| Acetic Acid SCHEMBL28060482 | 0.79 | KDM4E (0.38) | — | |
| SCHEMBL172309 | 0.78 | — | — | |
| SCHEMBL11393679 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102356075-B | Compositions and methods for inhibition of the jak pathway | RIGEL PHARMACEUTICALS INC | 2015-06-10 | — | — | CN | claimed |
| CN-102356075-A | Compositions and methods for inhibition of the jak pathway | RIGEL PHARMACEUTICALS INC | 2012-02-15 | — | — | CN | claimed |
| WO-2024129982-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220144759-A1 | COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160137785-A1 | POLY(BETA-AMINO ALCOHOLS), THEIR PREPARATION, AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-9182414-B2 | Methods for identifying a GLP-1 secretagogue | ARENA PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-7625906-B2 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20090270422-A1 | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto | ARENA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009040410-A1 | OXADIAZOLE- AND OXAZOLE-SUBSTITUTED BENZIMIDAZOLE- AND INDOLE-DERIVATIVES AS DGAT1 INHIBITORS | NOVARTIS AG (CH) | 2009-04-02 | — | — | WO | disclosed |
| US-7504506-B2 | Therapeutic compounds and uses thereof | ELIXIR PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7470699-B2 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-7425630-B2 | Processes for preparing pyrazolo[3,4-d]pyrimidine ethers | ARENA PHARMACEUTICALS, INC. (US) | 2008-09-16 | — | — | US | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072803-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-3994897-A | Process for the manufacture of carboxylic acids from methyl ketones | BASF AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |